GCIA
BMRN icon

Gabelli & Co Investment Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-7,850
Closed -$713K – 168
2017
Q2 		$713K Sell
7,850
-17,600
-69% -$1.6M 0.08% 96
2017
Q1 		$2.23M Buy
+25,450
New +$2.26M 0.25% 57

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gabelli & Co Investment Advisers's BMRN Position: Q3 2017 in Review

Gabelli & Co Investment Advisers sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2017, closing a stake of 7,850 shares — an estimated $713K sold.

Gabelli & Co Investment Advisers first reported a position in BMRN in Q1 2017 and held it in 2 quarters. The position peaked at $2.23M in Q1 2017. 411 funds tracked by Wall St. Rank hold BMRN as of Q3 2017.

  • Gabelli & Co Investment Advisers reported no remaining BioMarin Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 7,850 BioMarin Pharmaceuticals shares in Q3 2017, an estimated $713K.
  • Gabelli & Co Investment Advisers first reported a position in BioMarin Pharmaceuticals in Q1 2017 and held it in 2 quarters.
  • Gabelli & Co Investment Advisers's BioMarin Pharmaceuticals position peaked at $2.23M in Q1 2017.
  • 411 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2017.

Based on Gabelli & Co Investment Advisers's 13F filing for Q3 2017, filed 1 Nov 2017.